Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Anti-Tumor Cytotoxicity against Neuroblastoma

Hu14.18-IL15 and Hu14.18-IL21 exhibited robust preclinical activity, warranting further consideration for clinical testing in patients with GD2-expressing neuroblastoma.